Benchmark analyst Mike Hickey maintains Imax (NYSE:IMAX) with a Buy and lowers the price target from $28 to $25.
What’s Going On With Obesity Drug-Developer Altimmune Inc Stock?
Altimmune, Inc. (NASDAQ: ALT) shares are trading higher Thursday, and the stock has gained more than 140% over the past month.